Budapest, Hungary-based Mediso Medical Imaging Systems has completed the first phase of a strategic technology transfer agreement with Superconducting Systems (SSI), a fully owned subsidiary of MRI technology developer IMRIS.
Over the past decade, Mediso has used SSI’s fully cryogen-free superconducting magnets, resulting in the launch of the nanoScan 3-tesla and 7-tesla MRI systems, Mediso said.
With the initial phase of the transfer now complete, Mediso is ramping up its European magnet manufacturing capabilities, the company added. Full-scale production is expected to be operational by the end of the year, incorporating Mediso’s quality management systems into serial production processes.
Further, the transferred technology grants Mediso access to SSI’s foundational intellectual property and patented technologies for the field of preclinical MRI, enabling the development of conduction-cooled superconducting magnets with bore sizes optimized up to 9.4 tesla, Mediso noted.
Founded in Chaska, MN, in 2005, IMRIS designs, manufactures, and services proprietary intraoperative MRI suites used by hospitals and cancer centers worldwide. IMRIS developed a movable MRI that operates on a ceiling-mounted rail system so that it can glide between a diagnostic room and operating room, according to Grovecourt Capital Partners, the private equity firm that acquired IMRIS earlier this year.
